Pfizer Global Medical Grants (GMG) Request for Proposals (RFP) Real World Experience with Biosimilar Medicines in Oncology
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Thursday 5th, May 2022
External Deadline: Tuesday 10th, May 2022
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Geographic Scope: Global
Clinical Area: Oncology – General -– Biosimilars
Link to full RFP: Real World Experience with Biosimilar Medicines in Oncology
Application Due Date: May 10, 2022
Specific Area of Interest: Medical education projects that will be considered for Pfizer grant support will focus on increasing the awareness and understanding of real-world experience with oncology monoclonal antibody biosimilars and the health economic considerations of biosimilars to providers, patients, and stakeholders.
There is an emerging body of real-world data on biosimilars that were previously lacking. The goal of this RFP is to apply and convey the retrospective body of real-world data in oncology biosimilars to enhance understanding of real-world experiences, including implementation, switching, and health economics. Of particular interest are biosimilars used in the treatment of lymphoma, colorectal and lung cancer, and breast cancer.